IngredientsGardenia jasminoides Ellis is a popular shrub in the Rubiaceae family. Also known as "Cape Jasmine," it is an East Asian blooming species indigenous to East Asia. It is also commonly named gardenia, cape jasmine, or cape jessamine, and is a popular evergreen shrub. In traditional Chinese medicine, the plant is known by the name Zhizi (栀子), while its dried ripe fruit is referred to pharmaceutically as Gardeniae Fructus. The species is a member of the Rubiaceae (coffee) family.
G. jasminoides is distributed in the tropical and subtropical regions of the world, especially in south of the Yangtze River of China. The fruit is harvested when mature and dried, developing its characteristic deep yellow-orange color. The fruit is an ovoid, yellow or yellow-orange berry containing slightly bent seeds.
Gardenia fruit (GF) is the mature fruit of Gardenia jasminoides Ellis, boasting a rich array of nutrients and phytochemicals. Over time, GF has been extensively utilized in both food and medicinal contexts. Gardenia fruit, roots, leaves, seeds, and blossoms can all be used medicinally.
Gardenia flowers can be eaten raw, pickled, or preserved in honey. In China, the petals are used in tea for their aroma, while a yellow-red dye used in textiles and sweets has been extracted from the pulp of the fruit. Industrial applications for GF include utilizing gardenia yellow/red/blue pigments in the food industry and incorporating it with other herbs in traditional Chinese medicine.
Common preparation forms include: dried whole fruit (for decoction), standardized aqueous or ethanolic extracts of the fruit, isolated constituent preparations (especially geniposide and crocin), and the plant's pigments as food colorants. Gardenia yellow pigment has been the most important source of a natural colorant for food, cloth, and paint for thousands of years.
Its dried fruits, used as a traditional herbal medicine, were first recorded in the book named Shennong Ben Cao Jing (the Classic of Herbal Medicine in China). Zhi Zi (the TCM name for Gardenia jasminoides fruit) has been recorded in Chinese medical texts for over two thousand years and appears in classical formulas such as Zhi Zi Chi Tang, traditionally used to address irritability and restlessness caused by heat.
Zhi Zi (Gardenia jasminoides), commonly known as Gardenia Fruit, is a widely used heat-clearing herb in Traditional Chinese Medicine (TCM). For centuries, it has been valued for its ability to drain fire, eliminate irritability, clear heat, and cool the blood. In classical Chinese herbal medicine, Zhi Zi is frequently included in formulas designed to clear heat from the heart, liver, and lungs, relieve restlessness, and eliminate toxic heat from the body.
Called zhi-zi in traditional Chinese medicine, it was a folk remedy for jaundice, oedema, and fevers. It is classified as a "Middle grade" drug and is recorded in the Chinese pharmacopoeia with various effects, such as eliminating vexation, reducing fever, and cooling blood.
The herb has also been processed in China according to the record in the Treatise on Febrile Diseases and it is considered a medicine-food homology by the National Health Commission of the People's Republic of China. The Ministry of Health has listed it as one of the first pharmaceutical or food resources.
YCHT (Yin-Chen-Hao-Tang) is an aqueous extract derived from three herbs: Artemisia capillaries Thunb (Herba Artemisiae Capillaris, Yin-Cen-Hao), Gardenia jasminoides Ellis (Fructus Gardeniae, Zhi-zi) and Rheum officinale Baill (Emodin, Da-huang), with a ratio of 4:3:1 in weight. Yin-Chen-Hao-Tang decoctions have long been used as anti-inflammatory, antipyretic, choleretic, and diuretic agents for liver disorders and jaundice.
In addition to its use in traditional Chinese medicine, G. jasminoides has been widely used in folk medicine in Japan and Korea for hundreds of years to treat fever, gastrointestinal issues, and inflammation. Shishihakuhito is a Chinese herbal medicine mainly composed of gardenia fruit and is used to treat atopic dermatitis.
In ethnic, traditional, and folk medicine, GJE has been used to treat fever and cold and relieve nervous anxiety. Gardenia jasminoides is used in traditional Chinese medicine for various properties, including emollients, emetics, diuretics, vermifuge, antispasmodics, antiseptics, and analgesics. The dried fruit and fresh blossoms and leaves have traditionally been made into tea used to calm nerves, treat diabetes, and help with sleep.
Approximately 162 compounds have been isolated and identified from this medicinal plant. Iridoid glycosides and yellow pigment are generally considered the main bioactive and characteristic ingredients, and geniposide is used as an indicator. An examination uncovers a variety of bioactive phytoconstituents, such as flavonoids, iridoid glycosides, gardenia's yellow pigment, monoterpenoids, sesquiterpenoids, triterpenoids, organic acids and their derivatives, along with other compounds.
A number of chemical components of G. jasminoides have been isolated and characterized, including iridoids, iridoid glucosides, triterpenoids, organic acids, and volatile compounds. Geniposide, genipin, gardenoside, crocin, and iridoids are the major bioactive compounds found in G. jasminoides. The major volatile compounds in essential oil of G. jasminoides are aliphatic acids, ketones, aldehydes, esters, alcohols, and aromatic derivatives.
Geniposide (C17H24O10), a well-known iridoid glycoside compound, is one of the main bioactive components of traditional Chinese medicine Gardeniae Fructus, the dried ripe fruit of Gardenia jasminoides Ellis (Zhizi in Chinese). This compound is also considered as a glycoside consisting of one molecule of genipin and one molecule of glucose.
Genipin reduces insulin resistance, demonstrates antidepressive and antithrombotic effects, provides protection against liver damage, and inhibits gastric lesions. The active mechanisms are related to enhancement of SOD, GSH, CAT, IDE, PPARγ, and FoxO1, inhibition of ROS, NO, ALT, AST, and α-synuclein, and regulation of signaling pathways such as AMPK, NF-κB, and PI3K/Akt.
After oral administration of genipin and geniposide, genipin sulfate was a major metabolite in the bloodstream, whereas the parent forms of genipin and geniposide were not detected.
Regarding concentration in the fruit: The geniposide content in G. jasminoides fruit showed a trend of decrease from 60 days after flowering (DAF) to 120 DAF, then remained steady during the fruit ripening stages. The highest concentration was 2.035 ± 0.004% in the early stage at 60 DAF when the fruit was young and bluish green.
Crocin — a water-soluble carotenoid — is found in the fruits of gardenia (Gardenia jasminoides Ellis) and in the stigmas of saffron (Crocus sativus Linne). Crocin has many medicinal effects such as antioxidant and anti-inflammatory activities, is antihyperlipidemic, and is protective of the injured liver.
Crocin-I content in G. jasminoides fruit showed a continuous increase from 0.519 ± 0.039% in young fruit (60 DAF) to the highest cumulative amount of 1.098 ± 0.020% in matured fruit (180 DAF).
Numerous studies have shown crocins to be capable of a variety of pharmacological effects, such as protection against cardiovascular diseases, inhibition of tumor cell proliferation, neuroprotection, and protection of hepatocytes. Among the mechanisms underlying their various protective actions, the antioxidant activity was hypothesized to be responsible for various pharmacological effects of crocins.
The principal bioactive and distinguishing components of Gardenia are widely regarded as iridoids (geniposide, genipin) and crocins (crocetin, crocin, crocin II). Shared compounds (crocin, crocin II, geniposide, genipin, and crocetin) have demonstrated significant pro-proliferative effects on LPS-induced RAW 264.7 cells and inhibitory effects on inflammatory factors NO, TNF-α, IL-6, and IL-1β in pharmacological studies.
The chemical constituents present in Gardenia plants include triterpenes, carotenoids (e.g., crocins), iridoid glycosides, quinic acid derivatives, amides, and fatty acids. Some preparations have also been found to contain polyphenolic compounds. Additional isolates from the flowers of wild Gardenia jasminoides include iridoids such as coumaroylshanzhiside derivatives and a phenylpropanoid glucoside.
Geniposide plays an anti-inflammatory role via regulating TLR4 and downstream signaling pathways in lipopolysaccharide-induced inflammation in mice. Geniposide also suppressed arthritis in adjuvant-induced arthritis rats by decreasing the expression levels of tumor necrosis factor-α, interleukin (IL)-1β, and IL-6, increasing the production of IL-10, and inhibiting the expression of phospho-p38 (p-p38) related proteins.
Gardenia jasminoides is a widely used herbal medicine with anti-inflammatory properties. Investigation of whether 70% ethanolic GJ extract and its subsequent fractions inhibit ORAI1 (a calcium channel important in generating intracellular calcium signaling for T cell activation) revealed that the extract (64.7% ± 3.83% inhibition at 0.1 mg/ml) and all fractions showed inhibitory effects on the ORAI1 channel.
Purified crocin with purity of >99.6% has antioxidative activity at concentrations up to 40 ppm. At 20 ppm, the antioxidative activity of crocin is comparable to that of butylated hydroxyanisole (BHA). Geniposide and genipin further contribute to antioxidant activity through enhancement of superoxide dismutase (SOD), glutathione (GSH), and catalase (CAT) activity while suppressing reactive oxygen species (ROS).
A growing body of evidence shows that the neuroprotective benefit of geniposide probably arises from its agonist action on the glucagon-like peptide-1 receptor (GLP-1R). Geniposide, a bioactive iridoid glycoside isolated from Gardenia jasminoides Ellis, as well as an agonist of Glucagon-like peptide-1 receptor (GLP-1R), has been reported to exhibit antidepressant-like effects in several rodent models.
The hypoglycemic mechanism of α-glucosidase inhibitors works by inhibiting α-glucosidase in the intestinal mucosa, slowing the breakdown of starches into glucose and reducing absorption of glucose in the small intestine. Related studies showed that gardenia can effectively inhibit the activity of α-glucosidase.
Genipin suppressed intracellular lipid accumulation caused by free fatty acid treatment and also significantly increased the intracellular expression of a fatty acid oxidation-related gene (peroxisomal proliferator-activated receptor PPARα). These results confirmed that geniposide has an anti-obesity effect, an insulin resistance-alleviating effect, and an abnormal lipid metabolism-alleviating effect, and the metabolite genipin shows a direct effect on the liver, inducing expression of a lipid metabolism-related gene as one of its molecular mechanisms.
In animal models, Gardenia jasminoides significantly reduced liver mRNA and/or protein expression of transforming growth factor β1 (TGF-β1), collagen type I (Col I), and α-smooth muscle actin (α-SMA). It significantly suppressed the upregulation of these fibrotic markers in human hepatic stellate cells (LX-2) exposed to recombinant TGF-β1, and inhibited TGF-β1-induced Smad2 phosphorylation in LX-2 cells.
The polysaccharide fraction of G. jasminoides (GPS) also inhibited the Toll-like receptor 4 (TLR4)/nuclear factor kappa-B (NF-κB) signaling, decreased the expression of inflammatory factor genes, and ameliorated hepatic inflammation.
Preclinical evidence (animal and in vitro): Treatment with Gardenia jasminoides decreased serum alanine aminotransferase (BDL vs BDL + 100 mg/kg Gardenia jasminoides: 146.6 ± 15 U/L vs 77 ± 6.5 U/L, P = 0.0007) and aspartate aminotransferase (188 ± 35.2 U/L vs 128 ± 19 U/L, P = 0.005) as well as hydroxyproline (438 ± 40.2 μg/g vs 228 ± 10.3 μg/g liver tissue, P = 0.004) in bile duct-ligated rats.
In a mouse model of acetaminophen (APAP)-induced liver injury, levels of serum hepatic transaminases and inflammatory markers, including IL-6 and TNF-α, significantly decreased in mice treated with Gardenia jasminoides fruit extract compared to those in the APAP group, with significant improvement in hepatic histology and hepatic GSH levels also observed.
In a cholestatic mouse model, GPS administration dose-dependently ameliorated impaired hepatic function, including a 2–7-fold decrease in aminotransferase levels, upregulated the expression of farnesoid X receptor (FXR) and pregnane X receptor (PXR) and their downstream efflux transporters, and decreased levels of 12 bile acids. Furthermore, GPS ameliorated gut microbiota dysbiosis, improved intestinal barrier function, and reduced serum and hepatic lipopolysaccharide levels 1.5-fold.
A study in a rat model of NASH with fibrosis induced by a high-fat, high-fructose diet investigated the therapeutic potential of GJE. Male Sprague-Dawley rats were assigned to groups including a low-dose GJE group treated with 0.119 g/kg BW of GJE and a high-dose GJE group treated with 0.239 g/kg BW of GJE. Gardenia jasminoides exhibits promising anti-inflammatory and anti-fibrotic properties in this model, suggesting its potential as a therapeutic candidate for NASH-related liver fibrosis.
Evidence strength: Evidence for hepatoprotective effects is primarily preclinical (rodent models and cell culture). There is a notable absence of robust controlled human clinical trials specifically evaluating Gardenia jasminoides fruit extract for liver disease endpoints. Several studies provide clinical evidence of effectiveness of the traditional compound formula YCHT (which includes gardenia) in the treatment of various liver diseases, but isolating the specific contribution of G. jasminoides from such multi-herb preparations in human studies has not been systematically done.
Preclinical evidence: The traditional use of Gardenia jasminoides as an anti-inflammatory agent has been confirmed in mouse models and in vitro. This plant has extensive utility in the history of Traditional Chinese Medicine and is acknowledged for its ability to combat inflammation, safeguard liver health, and possess antioxidant capabilities.
Shishihakuhito, a Chinese herbal medicine mainly composed of gardenia fruit, is used to treat atopic dermatitis, and it inhibits immunoglobulin E (IgE)-mediated histamine release.
Evidence strength: Anti-inflammatory effects have been well-documented in cell culture and animal models. Human clinical evidence specific to isolated Gardenia jasminoides is limited, with most human application occurring via complex multi-herb formulations used in TCM or Kampo traditions.
Preclinical evidence: In spontaneously obese Type 2 diabetic mice, geniposide showed suppression of body weight and visceral fat accumulation, alleviation of abnormal lipid metabolism, and suppression of intrahepatic lipid accumulation. In addition, geniposide alleviated abnormal glucose tolerance and hyperinsulinemia, suggesting that geniposide has an insulin resistance-alleviating effect.
In studies evaluating geniposide and crocin I on type 2 diabetes mellitus, geniposide demonstrated the best effect, with the order of hypoglycemic potency ranked as geniposide > crocin I > crude extract of gardenia. Crocin obtained from water extracts of G. jasminoides was found to exhibit antihyperlipidemic effects; when crocin and crocetin were given to tested mice, triglyceride and total cholesterol were significantly decreased.
Evidence strength: Evidence is predominantly from animal and in vitro studies. Clinical data in humans with type 2 diabetes or metabolic syndrome using Gardenia jasminoides preparations is very limited and does not yet allow definitive efficacy conclusions.
Preclinical evidence: Recent studies have confirmed the significant efficacy of GJE for treating central nervous system (CNS) disorders, including Alzheimer's disease, Parkinson's disease, and major depressive disorder in preclinical settings; however, GJE has not been systematically evaluated in controlled human trials.
In studies using the repeated restraint stress (RRS)-induced depression model in mice, geniposide treatment significantly ameliorated depression-like behaviors induced by RRS, such as decreased sucrose preference, reduced locomotor activity, and extended immobility time in tail suspension and forced swimming tests.
An animal experiment showed that geniposide as a major compound in gardenia fruit could alleviate depression-like behavior in diabetic mice by enhancing brain-derived neurotrophic factor (BDNF) expression. Another research found that oil from GF exhibited anti-depressant effects via protein kinase A, cAMP response element-binding protein, and BDNF signaling.
Evidence strength: Evidence for neuroprotective and antidepressant effects is largely from animal models and mechanistic in vitro studies. Human clinical trial data are absent or very preliminary for these endpoints.
Human clinical evidence: A pilot study investigated the effect of crocetin (derived from Gardenia jasminoides Ellis) on sleep. The clinical trial comprised a double-blind, placebo-controlled, crossover trial of 21 healthy adult men with a mild sleep complaint, including two intervention periods of 2 weeks each, separated by a 2-week washout period. Objective sleep quality was measured using an actigraph, and subjective symptoms were assessed using St Mary's Hospital Sleep Questionnaire. Actigraph data showed that after administration of crocetin, the number of wakening episodes was reduced compared to that of the placebo (p=0.025).
Evidence strength: This is one of the few available human clinical studies. However, it is a small pilot study (n=21) and should be considered preliminary. The study evaluated crocetin specifically, not a whole-plant extract. Larger, more robust trials are needed before clinical conclusions can be drawn.
Numerous studies have confirmed that crocins and iridoid glycosides have effects of antioxidation, anti-inflammatory activity, anti-atherosclerosis, anti-ischemic brain injuries, anti-platelet aggregation, anti-hyperglycemia, anti-hyperlipidemia, and anti-hypertension. From basic pharmacological research of GJE extract on several rat models, GJE extract markedly prolonged bleeding time and inhibited platelet aggregation and thrombosis.
Evidence strength: Cardiovascular evidence is entirely preclinical (animal models and in vitro). No robust human clinical trials have specifically tested Gardenia jasminoides extracts for cardiovascular endpoints.
Genipin gentiobioside can treat heart failure, while geniposide, crocin 1, and crocin 2 are confirmed to have anti-cancer effects in colon and bladder cancer cell lines. Gardenoside has a demonstrated effect on HepG2 liver cancer cells cultured in vitro. These ingredients can induce cancer cell apoptosis through their influence on the expression of Bcl-2 and other genes, which may be the main mechanism for the anticancer effect.
The fruit of Gardenia jasminoides contains the natural iridoid geniposide, which has anti-inflammatory, antioxidant, anticancer, antidiabetic, hepatoprotective, and immunomodulatory properties.
Evidence strength: Anticancer evidence is exclusively from in vitro cell studies and animal models. There are no human clinical trials demonstrating anticancer efficacy of G. jasminoides preparations in oncology.
Gardenia jasminoides extract exhibited antioxidative and antiapoptotic effects in skin cells exposed to UVB radiation. UVB-induced injury and inflammatory responses of skin cells were attenuated by gardenia extract treatment.
Evidence strength: These findings are in vitro. No human clinical trial data are available in these sources to support dermatological use beyond the traditional Kampo application for atopic dermatitis.
Various pharmacological properties have been validated, including a beneficial effect on the nervous, cardiovascular, and digestive systems, hepatoprotective activity, antidepressant activity, and anti-inflammatory activity.
These components are implicated in wide-ranging pharmacological applications, which encompass antioxidant, anti-inflammatory, anti-diabetic, cardiovascular disorders, neurodisorders, anti-tumor, treatment of liver injury, anti-hepatic injury, gastrocellular activity, improvement of gut microbiota, atopic dermatitis, anti-viral, improvement of the quality of sleep, protection from blue light and ultraviolet rays, vitiligo, inhibition of retinal damage, antibacterial activity, anti-senescence activity, anti-thrombosis, osteoporosis protection, and postmenopausal syndrome.
The following dosages are those reported in specific studies as cited; they are not recommendations.
One of the most significant and well-characterized safety concerns for Gardenia jasminoides is the paradoxical hepatotoxicity of its major active constituent at high doses. Although geniposide has a wide range of biological activities, its toxicity needs to be addressed. Hepatotoxicity is a fundamental issue affecting the safety of geniposide. A study in rats revealed that high doses of geniposide (574 mg/kg or more) cause acute hepatotoxicity after 24–48 hours of oral administration — an effect that may be related to oxidative stress — whereas normal doses of geniposide (24.3 mg/kg or less) do not cause hepatotoxicity, even when repeatedly administered for 90 consecutive days.
The hepatotoxicity was associated with oxidative stress, including decrease of total superoxide dismutase activity and increase of malondialdehyde concentration in rats' livers. In addition to normal rats, rats with α-naphthyl isothiocyanate (ANIT)-induced cholestasis also exhibit hepatotoxicity after geniposide administration, resulting in severe pathological damage to the liver.
Geniposide, a major active constituent of the traditional medicinal herb Gardenia jasminoides ELLIS fruit, exhibits remarkable anti-inflammatory, antiapoptotic, and antifibrotic properties and has been used in a variety of medical fields, mainly for the treatment of liver diseases. However, geniposide-induced hepatotoxicity has been an area of ongoing investigation.
The intestinal damage caused by geniposide, including necrosis of intestinal epithelial cells and destruction of tight junction structures, precedes liver damage at high doses. Intestinal microbiota-mediated covalent modification of hepatic proteins by genipin dialdehyde may play a crucial role in the liver injury of geniposide, highlighting the contribution of intestinal microbiota to the metabolic activation of this compound.
A clinically significant and well-documented adverse effect associated with long-term use of Gardenia jasminoides-containing preparations is idiopathic mesenteric phlebosclerosis (IMP). Many recent reports have suggested a possible association between Japanese traditional (Kampo) medicines containing Gardeniae Fructus (GF) and mesenteric phlebosclerosis (MP). MP is a chronic orphan disease characterized by venous calcification extending from the colonic wall to the mesentery, usually developing in the proximal colon.
Which Chinese herb is the culprit in MP cases is often unclear, but extracts of Gardenia jasminoides have been reported to be responsible. Hiramatsu et al. showed that 70.4% of IMP patients have exposure to sanshishi, which is an extract of Gardenia jasminoides.
While mechanisms are not entirely clear, it is possible that geniposide, the main component of Gardenia jasminoides, may be transferred to genipin, which is absorbed into the mesenteric veins and causes intimal hyperplasia, venous wall thickening, and fibrosis, resulting in "mummification," with subsequent obstruction of venous lumen producing inadequate venous return, intestinal wall thickening, edema, gliosis, and sclerosis, eventually progressing to mesenteric phlebosclerosis.
Clinical research has shown that patients administered a formulation containing Gardenia jasminoides Ellis have exhibited mesenteric venous sclerosis (MP), a chronic ischemic condition marked by mesenteric venous sclerosis of uncertain origin.
It is suggested that genipin, a metabolite of geniposide (the major ingredient of gardenia fruit), is involved in bronze coloration observed with long-term use. A patient who took the extract of gardenia fruit for 7 years developed skin pigmentation complicated with mesenteric phlebosclerosis. In 2020, a case of someone who had developed blue-gray discoloration of the skin as a result of chronic intake of gardenia fruit extract was published.
In long-term animal administration studies, a significant decrease in body weight gain and food consumption occurred in the 2% GF group, and pigmentation of the liver, kidney, and spleen in macroscopic or histopathological examination was observed after 11-month administration, which disappeared after a 3-month recovery period.
Herb–herb combinations, such as the combination of Gardenia jasminoides Ellis (ZZ) with Fructus aurantii immaturus (ZS) and/or Cortex magnoliae officinalis (HP), may increase the absorption of geniposide and increase its oral bioavailability. This has implications for potential changes in both therapeutic and toxic effects when G. jasminoides is used as part of traditional herbal formulations.
Rats with α-naphthylisothiocyanate (ANIT)-induced cholestasis exhibit hepatotoxicity after geniposide administration, resulting in severe pathological damage to the liver, suggesting caution is warranted in individuals with pre-existing bile flow impairment.
Health conditions that Gardenia jasminoides may help support.
Gardenia jasminoides extracts, particularly crocin and geniposide, have demonstrated potent antioxidant activity in multiple in vitro and in vivo studies including free radical scavenging, SOD restoration, and lipid peroxidation inhibition. Genipin is described as a specific hydroxyl radical scavenger. An in vitro antioxidant study of GJ fruit extracts was published in Food Chemistry (2011).
Fructus Gardeniae (FG) has demonstrated anxiolytic-like effects in preclinical rodent models, primarily by modulating neuroinflammation and gut-brain axis signaling. In a rat model of sleep-deprivation-induced anxiety, FG reduced pro-inflammatory cytokines (TNF-α, IL-1β) in the hippocampus and restored gut microbiota balance, correlating with reduced anxiety-like behavior in open-field and elevated plus-maze tests. Human clinical evidence remains absent.
Geniposide from Gardenia jasminoides has demonstrated anti-arthritic effects in adjuvant-induced arthritis rat models, suppressing synoviocyte hyperpermeability via RhoA/p38MAPK/NF-κB/F-actin pathways and reducing joint inflammatory cell infiltration. Anti-osteoporosis effects relevant to bone-joint health have also been identified. Evidence is preclinical.
Geniposide from Gardenia jasminoides has demonstrated antithrombotic activity and inhibition of platelet aggregation in preclinical studies, as documented in multiple pharmacological reviews. This is listed among geniposide's established pharmacological activities in peer-reviewed literature. Human clinical evidence is absent.
Gardenia jasminoides demonstrated antihypertensive effects in an L-NNA-induced hypertension mouse model, with geniposide identified as the primary active component. GJ-treated mice showed significantly lower systolic, diastolic, and mean blood pressure vs. controls. A 2025 human study also showed gardenia floral volatiles reduced blood pressure and pulse in college students.
Multiple preclinical studies demonstrate that Gardenia jasminoides and its active components geniposide and crocin I exert hypoglycemic effects in type 2 diabetic animal models. Mechanisms include UCP2 inhibition by genipin (stimulating pancreatic beta-cell insulin secretion), GLP-1 receptor agonism by geniposide, and reduced oxidative stress in islet cells. No human clinical trials have confirmed these effects.
A 2025 human study published in Scientific Reports found that the floral volatiles of Gardenia jasminoides (rich in terpenes and linalool) measurably reduced physiological stress markers in college students, including increased alpha-wave power and reduced beta-wave power. These compounds are associated with nervous system regulation and sedative effects. The study was controlled but limited in scope.
A glycoprotein isolated from Gardenia jasminoides reduced plasma total cholesterol, triglycerides, and LDL in mice (Clin Exp Pharmacol Physiol, 2006). Crocin inhibits pancreatic lipase activity in vitro to reduce lipid absorption. These hypolipidemic effects have been identified as relevant to TCM's traditional use of Fructus Gardeniae in metabolic conditions.
Genipin and geniposide from Gardenia jasminoides have been well characterized as anti-inflammatory agents in multiple preclinical models, acting by suppressing NF-κB, MAPK, and AP-1 signaling pathways and inhibiting pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, NO). These effects have been documented across carrageenan-induced edema, LPS-induced macrophage activation, colitis, arthritis, and pancreatitis models. Human data are lacking.
Gardenia jasminoides extracts (crocin-rich GJ-4) protected against cognitive decline in APP/PS1 transgenic Alzheimer's disease mice over 12 weeks of oral treatment. Genipin and crocin also protect against age-related neurodegeneration via anti-inflammatory, antioxidant, and tau-phosphorylation-reducing mechanisms. Evidence is from animal models of neurodegeneration.
Crocin and the iridoid fraction of Gardenia jasminoides have demonstrated antidepressant-like effects in multiple preclinical rodent models of depression (CUMS, forced-swim, tail-suspension tests) via PKA-CREB signaling pathway activation and modulation of the HPA axis. Geniposide has also shown antidepressant activity in chronic unpredictable mild stress models. No human RCTs have been completed.
Gardenia jasminoides extract has shown efficacy against atopic dermatitis (eczema) in multiple mouse models via inhibition of Th2-mediated inflammatory responses, suppression of IgE and histamine, and restoration of skin barrier proteins. Geniposide is identified as a key active constituent for these anti-allergic effects. Evidence remains preclinical.
Gardenia jasminoides (Fructus Gardeniae) has been used for millennia in TCM as a primary antipyretic herb. Modern pharmacological evidence shows geniposide exerts antipyretic effects in febrile rats by modulating the TLR4/NF-κB signaling pathway, a mechanism published in the Journal of Ethnopharmacology (2024). The antipyretic mechanism has also been explored via plasma metabolomics in yeast-induced fever rat models.
Gardenia jasminoides is a core component of the classical TCM formula Yinchenhaotang, prescribed for cholestatic liver and gallbladder disorders. Geniposide and crocins promote bile flow (choleretic effect) and protect against bile acid-induced liver and bile duct injury in animal models. Traditional and preclinical scientific evidence is strong; human clinical data is mainly for the multi-herb formula.
Gardenia jasminoides (as part of Yinchenhaotang and as a standalone extract) has demonstrated choleretic (bile-flow promoting) effects and protection against bile acid-induced cholestasis and bile duct injury in animal models. Geniposide and crocins promote biliary secretion in rats. The formula containing gardenia is officially used clinically in Japan and China for cholestatic disorders.
Gardenia jasminoides fruit extract (GJE) has shown gastroprotective effects against both NSAID-induced gastropathy and H. pylori-induced gastritis in rat models, by inhibiting NF-κB and iNOS signaling, restoring prostaglandin E2 and mucin expression, and reducing bacterial growth and mucosal inflammation. Evidence is preclinical; human clinical studies have not been completed.
Gardeniae fructus (Gardenia jasminoides fruit) demonstrated significantly greater GLP-1 secretion than positive control EGCG in an in vitro assay. Two of its ligands—3-epioleanolic acid and crocin—were predicted to bind to the active GLP-1 receptor, suggesting potential as GLP-1 receptor agonists.
Geniposide from Gardenia jasminoides is metabolized by intestinal bacteria into genipin, making the gut microbiome central to its bioavailability and pharmacological activity. GJE has been shown to modulate gut microbiota composition in T2DM and sleep-deprivation models, and to protect intestinal mucosal integrity by upregulating tight junction proteins and suppressing pro-inflammatory cytokines. These are preclinical findings.
Geniposide from Gardenia jasminoides has been shown to protect against myocardial dysfunction and ischemia-reperfusion injury in preclinical models, via anti-inflammatory, anti-apoptotic, and antioxidant mechanisms. A 2022 PMC review (Molecules) identified 'anti-myocardial dysfunction effect' among geniposide's confirmed pharmacological activities. Evidence is entirely preclinical.
A double-blind, placebo-controlled, crossover clinical trial of 21 healthy adult men found that crocetin (a carotenoid from Gardenia jasminoides) reduced the number of wakening episodes as measured by actigraph (p=0.025) over 2 weeks. Geniposide and gardenoside have also shown sedative properties in animal models. This is the primary human evidence for this indication.
Genipin from Gardenia jasminoides inhibits UCP2 in pancreatic beta cells, reversing obesity- and high-glucose-induced insulin secretion dysfunction. Geniposide acts as a GLP-1 receptor agonist to enhance glucose-dependent insulin release. In aged rats, genipin administration significantly reduced hyperinsulinemia and hyperglycemia. These are preclinical mechanistic findings.
Gardenia jasminoides has extensive preclinical evidence for hepatoprotective and cholagogic (bile-promoting) effects. Key constituents geniposide and crocins protect against chemical-induced liver injury (CCl4, ANIT, acetaminophen, alcohol), reduce ALT/AST enzyme elevations, and promote bile flow. It is a core herb in the TCM liver-jaundice formula Yinchenhaotang, which has clinical use in Japan and China.
Gardenia jasminoides extracts (particularly crocin-rich fractions) have reversed memory loss in Drosophila and mouse Alzheimer's disease models. Crocin from gardenia protects hippocampal neurons from oxidative damage, modulates MAPK to suppress tau phosphorylation, and reduces neuroinflammation—effects linked to improved spatial cognitive performance in rodents. Evidence is preclinical.
Gardenia jasminoides and its constituents have been studied in high-fat diet rodent models of metabolic syndrome, demonstrating effects on blood glucose, blood lipids (triglycerides, cholesterol), and gut microbiota remodeling. A 2024 PMC study demonstrated attenuation of glycolipid metabolism disorder in HFD rats via gut microbiota targeting and TLR4/Myd88/NF-κB pathway. Evidence is preclinical.
Gardenia jasminoides was shown to protect against cerulein-induced acute pancreatitis in mice (C57BL/6), significantly reducing pancreatic edema, amylase/lipase levels, and lung injury in a dose-dependent manner. Geniposide has also been identified as a promising therapeutic for acute pancreatitis by ameliorating acinar cell injury and oxidative stress. Evidence is preclinical.
Geniposide and genipin from Gardenia jasminoides have demonstrated neuroprotective effects against dopaminergic neuron loss in MPTP-induced Parkinson's disease mouse models, mediated by anti-inflammatory and anti-apoptotic mechanisms. Crocin reversed depression-like behavior in a PD mouse model via VTA-mPFC dopaminergic pathway modulation. Evidence is entirely preclinical.
Gardenia jasminoides extract and geniposide have demonstrated anti-allergic activity relevant to urticaria (hives) and inflammatory skin reactions, primarily by inhibiting histamine release from mast cells and suppressing IgE and Th2 cytokines. These effects have been confirmed in mast cell lines and multiple AD mouse models. Evidence is preclinical.
Geniposide from Gardenia jasminoides demonstrated anti-rheumatic activity in adjuvant-induced arthritis rat models, inhibiting synoviocyte hyperpermeability via RhoA/p38MAPK/NF-κB/F-actin signaling and reducing paw swelling and synovial inflammation. It is listed in preclinical literature as a therapeutic candidate for rheumatoid arthritis alongside IBD and neurodegenerative disorders.
A double-blind, placebo-controlled clinical trial in 40 female volunteers found that a Gardenia jasminoides extract stabilized in Natural Deep Eutectic Solvent (NaDES) acted as a blue light filter and melatonin-like ingredient, reducing digital-stress-induced skin aging signs. Crocin within the extract also has documented antioxidant and anti-inflammatory effects on human keratinocytes and fibroblasts relevant to photoaging.
A double-blind, placebo-controlled crossover human trial showed that crocetin from Gardenia jasminoides reduced nighttime wakening episodes (objective actigraph, p=0.025) in men with mild sleep complaints over 2 weeks. Preclinical studies additionally show modulation of gut microbiota by GJE correlates with improved sleep quality metrics in rodents.
A 2025 human study (Scientific Reports) found that Gardenia jasminoides floral volatiles reduced physiological stress markers in college students—specifically decreasing beta-wave power, skin electrical signal, and blood pressure, while increasing alpha-wave power and HRV. Preclinically, gardenia modulates the HPA axis stress response and reduces hippocampal neuroinflammation in stress models.
A glycoprotein from Gardenia jasminoides reduced plasma triglycerides in mice (Clin Exp Pharmacol Physiol, 2006). Geniposide has been confirmed to regulate blood lipids in multiple preclinical studies, and gardenia extract reduced triglycerides and lipid peroxidation in high-fat diet rodent metabolic models. Evidence is preclinical.
Gardenia jasminoides fruit extract (GJE) protected against NSAID-induced gastric ulcers in rats by restoring the cytoprotective factors PGE2 and MUC5AC and suppressing iNOS and NF-κB. Geniposide also protects gastric mucosa and is formally listed among geniposide's therapeutic activities. Evidence is from animal models.
Fructus Gardeniae is documented in TCM for abdominal pain and discomfort associated with heat and dampness patterns, including 'blood strangury with astringent pain.' The Chinese Pharmacopoeia formally records this indication. Geniposide has demonstrated analgesic effects in preclinical writhing tests, providing some mechanistic support.
Fructus Gardeniae is documented in classical TCM texts and modern ethnopharmacological reviews as a traditional treatment for headaches, typically attributed to 'liver fire rising.' This use is recorded in the Shennong Bencao Jing and subsequent materia medica. No clinical trials have been conducted specifically for headache.
Fructus Gardeniae is documented in TCM for 'eliminating vexation' and treating stomach upset and nausea associated with heat conditions. It is included in TCM formulas such as Zhi-zi-chi decoction for vomiting and restlessness. Preclinical evidence for gastric motility or anti-emetic effects is limited; no human clinical trials specifically address nausea/vomiting.
Gardenia jasminoides is traditionally used in TCM formulas for insomnia, including Zhi-zi-chi decoction, for difficulty falling asleep associated with heart fire and restlessness. Preclinical evidence shows geniposide and gardenoside have sedative properties in animal models. The 2010 crocetin human trial did not measure sleep onset latency specifically.
Fructus Gardeniae is documented in the Chinese Pharmacopoeia for external application to treat 'writhing and contusion pain,' which encompasses sprains and soft tissue injuries. This is a well-established traditional use in TCM supported by its anti-inflammatory and analgesic properties, though no clinical trials specifically for sprains exist.
Fructus Gardeniae is documented in the Chinese Pharmacopoeia for external use on 'fire toxin sores and sores' and contusion pain, representing traditional wound healing use. Genipin, a crosslinking agent derived from geniposide, has been studied as a biomaterial crosslinker relevant to wound healing but not as a direct oral/topical therapeutic in wound healing RCTs.
Body systems that Gardenia jasminoides may help support.
Go back